Special Supplement: Reports from the 34th San Antonio Breast Cancer Symposium and the 53rd American Society of Hematology Annual Meeting

The ASCO Post presents this special supplement with comprehensive coverage of important data from the 34th Annual San Antonio Breast Cancer Symposium and the 53rd American Society of Hematology Annual Meeting. In addition to news about the individual abstracts, experts offer their perspectives on how these reports impact clinical care.

Additional and continuing coverage of these important oncology meetings is also available in the February 15, 2012 issue of The ASCO Post. ■

34th Annual San Antonio Breast Cancer Symposium

HER2-positive Breast Cancer

• Dual HER2 Blockade Substantially Delays Disease Progression
• Bevacizumab Progression-free Survival Benefit Upheld in AVEREL Trial

Bisphosphonates in Early Breast Cancer

• Benefits of Some Bisphosphonates Confirmed in Breast Cancer Outcomes, but Questions Remain
  

Tumor Molecular Profiling

• Can Molecular Profiling Identify ER-positive Patients Destined for Relapse?
  

Metastatic Breast Cancer

• Everolimus plus Exemestane Significantly Prolongs Remission in BOLERO-2

53rd American Society of Hematology Annual Meeting

Lymphoma

• Post-CHOP Radioimmunotherapy Comparable to Rituximab Given along with CHOP in Previously Untreated Follicular Lymphoma
  

Leukemia

• BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
• Ponatinib Continues to Impress in Patients with Leukemia
• Three Novel Agents Show Promise in Acute Lymphoblastic Leukemia 
• Novel Agent Efficacious in Chronic Lymphocytic Leukemia
• A Second Chance for Gemtuzumab in Acute Myeloid Leukemia

Multiple Myeloma

• Monoclonal Antibody Promising in Multiple Myeloma
• Next-generation Proteasome Inhibitors Will Improve Outcomes in Bortezomib-refractory Myeloma Patients
• New Immunomodulatory Drug Produces Impressive Phase II Results in Multiple Myeloma